Day: October 22, 2020

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.62937-45-5,D-Prolinamide,as a common compound, the synthetic route is as follows.

62937-45-5, A solution of 5-(4-chlorophenyl)-2-{ [l-(4-chloropyridin-3-yl) H-l,2,4-triazol-3-yl]methyl}-4- [(2S)-3,3,3-trifluoro-2-hydroxypropyl]-2,4-dihydro-3H-l,2,4-triazol-3-one (Example 6A, 150 mg, 300 muiotaetaomicron) in ethanol (600 mu) was treated with D-prolinamide (342 mg, 3.00 mmol) and heated at reflux overnight. The reaction mixture was purified by preparative HPLC (Method 4) affording 137 mg (79 % of th.) of the title compound. LC-MS (Method 2): Rt = 1.03 min; MS (ESIpos): m/z = 578.2 [M+H]+ -NMR (400 MHz, DMSO-d6) delta [ppm]: 8.73 (s, 1H), 8.27-8.00 (m, 2H), 7.80-7.50 (m, 4H), 7.30 (s, 1H), 7.10 (s, 1H), 6.91 (d, 1H), 6.52 (d, 1H), 5.19-4.99 (m, 2H), 4.40-4.20 (br m, 1H), 4.16-3.76 (m, 3H), 2.93-2.66 (m, 2H), 2.11-1.91 (m, 1H), 1.85-1.44 (m, 3H).

The synthetic route of 62937-45-5 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; BAYER AKTIENGESELLSCHAFT; BAYER PHARMA AKTIENGESELLSCHAFT; COLLIN-KROePELIN, Marie-Pierre; KOLKHOF, Peter; NEUBAUER, Thomas; FUeRSTNER, Chantal; POOK, Elisabeth; WITTWER, Matthias, Beat; LUSTIG, Klemens; TINEL, Hanna; LINDNER, Niels; SCHIRMER, Heiko; (449 pag.)WO2019/81307; (2019); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.135616-40-9,(R,R)-(-)-N,N’-Bis(3,5-di-tert-butylsalicylidene)-1,2-cyclohexanediamine,as a common compound, the synthetic route is as follows.

5,46 G (0,01 mol) (R, R)-2, 2′- [1, 2-Cyclohexandiyl) bis (nitrilomethylidyn)] bis [4,6-di- tert.-butyl)-phenol] (Illa) werden in 25 ml THF vorgelegt und mit 1,26 g (0,005 mol) VANADYLSULFAT-PENTAHYDRAT in 25 ml Ethanol versetzt. Nach drei Stunden unter Rueckfluss wird das Loesungsmittel abdestilliert, der Rueckstand in 50 mi Dichlormethan aufgenommen und die Loesung mit 300 ml Wasser gewaschen. Nach Phasentrennung, Trocknen der Loesung mit Natriumsulfat und Abdestillieren des Loesungsmittels erhaelt man 3,6 g gruenes, amorphes Pulver. Zusammensetzung des Gemischs nach HPLC (Gew. -%) : Komponente (I) : (II) : (III) =43% : 13% : 44 %.

135616-40-9, 135616-40-9 (R,R)-(-)-N,N’-Bis(3,5-di-tert-butylsalicylidene)-1,2-cyclohexanediamine 2733339, acatalyst-ligand compound, is more and more widely used in various fields.

Reference£º
Patent; CLARIANT GMBH; WO2004/55028; (2004); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

62937-45-5,62937-45-5, D-Prolinamide is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

General procedure: A stirred suspension of 2-chloro-N-(1-methyl-1H-imidazol-4-yl)furo[3,2-d]pyrimidin-4-amine (1b) (100 mg, 0.40 mmol), (S)-pyrrolidin-2-ylmethanol (122 mg, 1.20 mmol) in N-Methyl-2-pyrrolidinone (1 mL) was subjected to microwave irradiation at 150 C for 2 h. The reaction mixture was diluted with ethyl acetate (50 mL), washed with brine (2 x 20 mL), dried, filtered and concentrated in vacuum. The crude residue was purified by combiflash (silica gel, 12 g, eluting with chloroform/CMA-80) to afford (S)-(1-(4-((1-methyl-1H-imidazol-4-yl)amino)furo[3,2-d]pyrimidin-2-yl)pyrrolidin-2-yl)methanol (2a) (43 mg, 34 % yield) as a light yellow solid; NMR (300 MHz, DMSO-i) delta 9.90 (s, 1H, D20 exchangeable), 8.00 (d, J = 2.1 Hz, 1H), 7.44 (s, 1H), 7.42 (d, J = 1.4 Hz, 1H), 6.71 (d, J = 2.1 Hz, 1H), 4.94 (s, 1H, D2O exchangeable), 4.13 (s, 1H), 3.83 – 3.69 (m, 1H), 3.64 (s, 3H), 3.62 – 3.49 (m, 1H), 3.48 – 3.23 (m, 2H), 2.07 – 1.83 (m, 4H); MS (ES+): 315.4 (M+l), 337.5 (M+Na), (ES-): 313.4 (M- 1). HPLC purity: 98.70%.

62937-45-5 D-Prolinamide 447554, acatalyst-ligand compound, is more and more widely used in various fields.

Reference£º
Patent; BIOCRYST PHARMACEUTICALS, INC.; KOTIAN, Pravin, L.; BABU, Yarlagadda, S.; KUMAR, V., Satish; ZHANG, Weihe; LU, Peng-Cheng; RAMAN, Krishnan; (747 pag.)WO2018/232094; (2018); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.3779-42-8,3-Bromo-N,N,N-trimethylpropan-1-aminium bromide,as a common compound, the synthetic route is as follows.

COMPOUND 6; 5-[3,5-bis-(3-Trimethyla?imoiiio-prop3doxy)-phenyl3-15-undecyl- porphyrin dichloride; To a vigorously-stirred suspension of Compound 5 (80 mg, 0.14 mmol) and K2CO3 (230 mg, 1.7 mmol) in DMF (30 mL) is added (1- bromopropyl)-trimethylammomum bromide (0.3 g, 16.6 mmol) at 50 0C. The mixture is stirred at this temperature for 18 h. After removal of the DMF under reduced pressure, the residue obtained is dissolved in methanol (5 mL) and filtered through a pad of silica gel (depth 2 cm) supported on a steel frit (diameter 3.5 cm). After washing the pad with methanol (ca. IL) the crude product is eluted with acetic acidrmethanol .-water (3:2:1, by vol.). Appropriate fractions are collected and, after evaporation of the solvent under reduced pressure, the residue obtained is purified by chromatography on a column (2.5 x 40 cm) of Sephadex LH-20 eluting with n-butanol:water:acetic acid (5:4:1, by vol., upper phase). After removal of the solvent from appropriate fractions under reduced pressure, the residue obtained is dissolved in methanol (5 mL) and the solution is passed through a short column (3.5 x 20 cm) of anion exchange resin (Amberlite IRA 400, chloride form). After collection of the eluate, solvent is removed under reduced pressure and the residue obtained is dried under high vacuum to yield the dichloride salt as a violet solid.1H-NMR: deltaH (300Mz, CD3OD): 0.75 (t, 3J l.5 Hz, 3 H), 1.05-1.20 (m, 14 H), 1.45- 1.50 (m, 2 H), 2.05-2.15 (m, 4 H), 2.15-2.20 (m, 2 H)5 2.95 (s, 18 H), 3.35-3.45 (m, 4 H), 3.95 (t, 3J 7.5 Hz, 4 H), 4.55 (t, 3J 7.5 Hz, 2 H), 6.85 (m, 1 H)5 7.35 (m, 2 H), 8.85-8.90, 9.15-9.20, (3 x m, 8 H), 10.10 (s, 2 H)., 3779-42-8

As the paragraph descriping shows that 3779-42-8 is playing an increasingly important role.

Reference£º
Patent; DESTINY PHARMA LIMITED; WO2006/765; (2006); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

787-70-2, [1,1′-Biphenyl]-4,4′-dicarboxylic acid is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated,787-70-2

General procedure: A mixture of acid (0.2 mmol), alcohol (0.6 mmol) and GO (50 wt%, calculated with the mass of acid) in ethyl alcohol or DCE (1 mL) was placed in a test tube equipped with a magnetic stirring bar. The mixture was stirred at 100 C for 24 h. After the reaction was finished, filtered the GO, solvent was removed, and the residue was separated by column chromatography to give the pure sample.

The synthetic route of 787-70-2 has been constantly updated, and we look forward to future research findings.

Reference£º
Letter; Chen, Zhengwang; Wen, Yuelu; Fu, Yejuan; Chen, Hai; Ye, Min; Luo, Guotian; Synlett; vol. 28; 8; (2017); p. 981 – 985;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.51094-17-8,4,4′,4”,4”’-(21H,23H-porphine-5,10,15,20-tetrayl)tetrakis-Phenol,as a common compound, the synthetic route is as follows.,51094-17-8

COMPOUND 1; 5,10,15,20-tetralds-[4-(3-Trimeth34ammonio-propyloxy)-phenyl]- porphyrin tetrachloride; To a vigorously-stirred suspension of 5,10,15,20-tetrakis-(4-hydroxy- phenyl)-porphyrin (50 mg, 0.07 mmol) and K2CO3 (230 mg, 1.7 mmol) in DMF (20 mL), a solution of (l-bromopropyl)-trimethylammonium bromide (0.27 g, 1.05 mmol) in DMF (5 mL) is added dropwise at 5O0C during 30 mins. The mixture is stirred at 5O0C for 15 h. After removal of DMF under reduced pressure, the residue obtained is dissolved in methanol (5 mL) and filtered through a pad of silica gel (depth 2 cm) supported on a steel frit (diameter 3.5 cm). After washing with methanol (1 L), the pad is eluted with acetic acid. After evaporation of solvent from the eluate, the residue obtained is purified by chromatography on a column (2.5 x 40 cm) of Sephadex LH20 eluting with n- butanol: water: acetic acid (4:5:1, by vol., upper phase). The recovered material is dissolved in the minimum volume of methanol and the solution is passed through a short column (3.5 x 20 cm) of anion exchange resin (Amberlite IRA 40O5 chloride form). The recovered tetrachloride salt is dried under high vacuum and obtained as a violet solid. 1H-NMR: deltaH (300MHz, CD3OD): 2.35-2.50 (bs. 8 H), 3.25-3.35 (bs, 36 H), 3.65- 3.75 (bs, 8 H), 4.35 (m, 8 H), 7.30, 8.10 (2 x d, 3J 8.5 Hz, 16 H), 8.80- 9.00 (bs, 8 H).

51094-17-8 4,4′,4”,4”’-(21H,23H-porphine-5,10,15,20-tetrayl)tetrakis-Phenol 135438030, acatalyst-ligand compound, is more and more widely used in various fields.

Reference£º
Patent; DESTINY PHARMA LIMITED; WO2006/765; (2006); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

168646-54-6, 5,6-Diamino-1,10-phenanthroline is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

General procedure: The respective diketo compound and 1, 10-phenanthroline-5, 6-diamine were dissolved in methanol followed by catalytic amountof acetic acid and the mixture was refluxed for 5-6 h. The mixturewas cooled to room temperature and the solid separated wasfiltered, washed with small amount of cold methanol followed byhexane and dried well to get red colored product.

168646-54-6, The synthetic route of 168646-54-6 has been constantly updated, and we look forward to future research findings.

Reference£º
Article; Kothavale, Shantaram; Sekar, Nagaiyan; Dyes and Pigments; vol. 136; (2017); p. 31 – 45;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.14162-94-8,4-Chloro-2,2′-bipyridine,as a common compound, the synthetic route is as follows.

0.303 g (9.45¡Á10-4 mol) of compound 1 and 2 g of KOH were stirred in 10 mL of DMSO for 10 min. 0.645 g (3.38¡Á10-3) of 4-chloro-2,2′-bipyridine was added. The reaction mixture was continuously stirred under argon at 50 C. for 22 hrs. After reaction, the mixture was poured into 30 mL of water. Extraction with 100 mL of CH2Cl2 was tried when the solution was highly alkaline but it was found difficult to separate the two phases. After evaporation of CH2Cl2, the oil was purified by chromatography (silica gel treated with 20% triethylamine in hexane, elution 5-10% methanol in CH2Cl2 and pure methanol) and vacuum dried to afford a sticky transparent product. This was dissolved in methanol and precipitated in acidified water to yield 52 mg of white powder. The remaining water phase was adjusted to pH=8 with NH3H2O. The solution was further extracted with CH2Cl2 until no more bipyridine derivatives could be detected by TLC. After evaporation of CH2Cl2, the oil was purified by chromatography (silica gel treated with 20% triethylamine in hexane, elution 5-10% methanol in CH2Cl2, and pure methanol), vacuum dried and precipitated in acidified water to yield 223 mg of product. The yield for the combined product is 37%. 1H NMR (400 MHz, CDCl3) delta 8.63 (d, 3 H), 8.45 (d, 3H), 8.32 (d, 3 H), 7.4-8.2 (b, 4 H, NH4), 7.97 (d, 3 H), 7.76 (t,3 H), 7.26 (t, 3 H), 6.84 (dd, 3 H), 4.39 (s, 6 H, 3 CH2O), 3.72 (s, 2 H, CH2O), 3.38 (t,2 H, OCH2), 2.20 (t, 2 H, CH2), 1.53 (q, 2 H, CH2), 1.45. (q, 2 H, CH2), 1.0-1.2 (b, 12 H, 6 CH2)., 14162-94-8

14162-94-8 4-Chloro-2,2′-bipyridine 15207243, acatalyst-ligand compound, is more and more widely used in various fields.

Reference£º
Patent; Zhou, Ming; Roovers, Jacques; US2005/59834; (2005); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

485-71-2,485-71-2, Cinchonidine is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

General procedure: The alkaloid (12.3 mmol, 1 eq.) and the appropriate substituted benzylic halide derivative(12.3 mmol, 1 eq.) were dissolved in THF (40 mL) with addition of a trace of NaI. The mixture washeated to reflux overnight and then cooled and stirred at ambient temperature for 1 h. In most cases theproduct precipitated as an off-white solid, but where this was not the case and the mixture containedonly a small amount of solid or no solid at all, then diethyl ether (20 mL) was added dropwise.The solid was removed via filtration and washed with THF (50 mL) or ether:THF, (1:1, v/v, 50 mL)and was dried under reduced pressure at 40 C. Where the solid formed was not a fine powder it was then taken up in DCM and this solution was then added dropwise to rapidly stirring ether (100 mL).This usually gives a finely divided solid that could be filtered and dried. (Note: The cinchonine derivedPTCs are usually very insoluble. The quinidine derived PTCs are often completely soluble at the endof the reaction.) The di(t-butyl)benzyl PTC was prepared according to the standard procedure aboveand was filtered directly from the reaction mixture.

The synthetic route of 485-71-2 has been constantly updated, and we look forward to future research findings.

Reference£º
Article; Zhang, Tao; Scalabrino, Gaia; Frankish, Neil; Sheridan, Helen; Molecules; vol. 23; 7; (2018);,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.135616-40-9,(R,R)-(-)-N,N’-Bis(3,5-di-tert-butylsalicylidene)-1,2-cyclohexanediamine,as a common compound, the synthetic route is as follows.,135616-40-9

5.46 g (0.01 mol) of (R,R)-2,2′-[1,2-cyclohexanediyl)bis(nitrilomethylidyne)]-bis[4,6-di-tert-butyl)phenol] are initially charged in 50 ml of ethanol and admixed with 1.14 g (0.0045 mol) of vanadyl sulfate pentahydrate. After three hours under reflux and complete conversion (TLC monitoring), the solvent is distilled off, the residue taken up in 200 ml of dichloromethane and the solution washed with 100 ml of water. After phase separation, drying of the solution with sodium sulfate and distilling off the solvent, 5.4 g of bright green, amorphous powder (yield: 96% of theory, based on a vanadium:salen ligand ratio of 1:2) are obtained.

The synthetic route of 135616-40-9 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; Kirschbaum, Bettin; Fell, Rainer; US2004/236129; (2004); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI